Navigation Links
Universal Bioenergy, Inc. Expressly Disclaims Any Responsibility for the Content, Accuracy of Information, and Quality of Information Regarding Universal Published by Any Third-Party and Being Disseminated on the Internet
Date:1/27/2009

INVESTORS SHOULD ONLY RELY ON INFORMATION PUBLISHED BY UNIVERSAL

NETTLETON, Miss., Jan. 27 /PRNewswire-FirstCall/ -- Universal Bioenergy, Inc. (Pink Sheets: UBRG) announces that certain unauthorized inaccurate information is being published about Universal in an analyst report on BeaconEquity.com website, potentially other websites and publications, and an email spam concerning Universal.

After reviewing these materials, the company has found errors in statements concerning the company's status and capabilities. Universal Bioenergy, Inc. strongly urges potential investors to rely solely on our SEC filings or information produced directly by the company. Universal recommends investors disregard any information published by third-parties.

Universal is a developmental stage company with limited operating history. To date it has not generated any revenue. Anyone considering purchasing securities of this company should review its filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Universal Bioenergy, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting
2. Universal Bioenergy, Inc. Seeks Algae Feedstock Companies for Acquisition, Alliance, and Joint Venture Opportunities for Biodiesel Production
3. Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company
4. [video] Jacques Tizabi, CEO of Universal Detection Technology Discusses Latest Purchase Order on WallSt.nets 3-Minute Press Show
5. New Chromatography Detectors From Varian, Inc. Extend the Range of Universal Detection for HPLC and LC/MS
6. Carrington and Universal Harvest Sign Supply Agreement
7. EDDA Technology Introduces Universal Enterprise Solution - Enabling 2D/3D/4D Advanced Clinical Applications on Existing PACS Workstations
8. SyntheMed Files Universal Shelf Registration
9. Raj Khankari Named Bioenergy, Inc., CEO
10. International Diabetes Experts Call for Stepped-Up Action and Shared Responsibility to Curb Rising Global Diabetes Epidemic and Impact
11. Global Vision Recognized for Helping Pharmaceutical Companies Achieve Complete Artwork and Copy Accuracy in their Packaging Process
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2